Empagliflozin

Empagliflozin has been studied in 495 papers since 2016: 94 trials and 117 observational studies in people, 105 in animals, 23 in cells, 114 reviews; 325 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Cardiovascular Effects of a Broad Range of Interventions for Adults with Prediabetes: A Systematic Review of Randomized Controlled Trials”.

InterventionSGLT2 inhibitorsApproved 2014

495 papers study it26 more mention it732 findingsUpdated

PubChemChEBIMeSH

Part of Bryan Johnson's Blueprint

123 new papers in 30 daysSee all 509 papers on empagliflozin

At a glance

Empagliflozin lowers hospitalization and cardiorenal event risks in human trials, but frailty results differ between trials. Independent labs report reduced cellular senescence in cells, with an opposing result in mice. Some human papers declare ties to its developers, Boehringer Ingelheim and Eli Lilly.

732 findings in 276 papers from 2016 to 2026, 102 of them since April 2026

Independent labs found the same change in cells, mice and people. 172 independent labs in 43 countries; 298 trials, 80 about aging, 70 with no results posted.

“sotagliflozin (OR 0.50; 95% CI: 0.40-0.63;p-score=0.98), empagliflozin (OR 0.69; 95% CI 0.62-0.76; p-score=0.88), and metformin (OR 0.79; 95% CI 0.35-1.75; p-score=0.63) had lowest odds of mortality”
Comparative Efficacy of Obesity Treatments on Major Adverse Cardiovascular Events, Heart Failure, and All-Cause Mortality in Adults with Overweight and Obesity: A Systematic Review and Network Meta-analysisADA Scientific Sessions 2026 abstract2026doi:10.2337/db26-3089-lb

41 of its findings point the other way.

Cells, mice and humans: replicated by independent labs. Worms or flies: nothing yet.
  • 172 independent labs in 43 countries
  • 41 findings against
  • 298 trials, 80 about aging, 70 with no results posted
  • Funders: Boehringer Ingelheim and others
  • 143 of 687 findings with company ties
  • 92 of 298 trials sponsored by its developers
  • Human trial94
  • Humans115
  • Animals97
  • Cells22
  • In silico15

71 studies gave empagliflozin to people and measured what changed.

What changedDesignPeopleSource

down: Decreases hospitalization for heart failure or cardiovascular deathHR 0.91 with no DD criteria, 0.64 with 1, and 0.49 with ≥2; treatment trend P=.0014

Randomized trial5,988 peopleHeart failure with preserved ejection fraction; increasing baseline diastolic dysfunction criteriaEuropean journal of heart failure, Nov 5, 2026

down: Decreases TNF-alpha

down: Decreases mitochondrial reactive oxygen species production

Trial90 days11 peopleINOCA with coronary microvascular dysfunctionAHA Scientific Sessions 2026 abstract, Nov 2, 2026

down: Lowers the risk of postoperative atrial fibrillation12.9% versus 26.8%; OR 0.40, 95% CI 0.25–0.65

no change: Has no effect on life-threatening arrhythmias3 versus 7 patients; P = 0.33

no change: Has no effect on acute kidney injury

Randomized trialAt least 3 days before surgery until discharge (maximum 30 days)467 peopleBoth61.3 ± 9.0 yearsMidlife adults; Non-diabetic patients undergoing elective isolated coronary artery bypass graftingESC Congress 2026 abstract, Oct 26, 2026

down: Decreases PRO-C3Adjusted ratio of change 0.90, 95% CI 0.85–0.95; 10% relative reduction

no change: Has no effect on PRO-C6Adjusted ratio of change 0.99, 95% CI 0.95–1.03; P=0.54

Review of trials12 or 24 weeks380 people pooledPatient cohortsESC Congress 2026 abstract, Oct 26, 2026

up: Increases ≥5% body weight reductionOR 1.88, 95% CI 1.18–2.99

down: Decreases systolic blood pressure

Randomized trial180 days800 peopleChronic kidney disease and type 2 diabetesESC Congress 2026 abstract, Oct 26, 2026

What did studies of empagliflozin find?

451

Studies of empagliflozin measured 451 outcomes; the most studied are inflammation (17 studies), cellular senescence (13) and oxidative stress and ROS signaling (12).

Inflammation

downin mice9downin rats5downin human cells1downin mouse cells1+1

17 studies
  1. Empagliflozin decreases inflammation in mice (diabetic cardiomyopathy induced by high-fat diet and streptozotocin).

    “EX, EMPA, EX combined with EMPA intervention significantly attenuated inflammation cell infiltration”

    Animalsdiabetic cardiomyopathy induced by high-fat diet and streptozotocinheart8 weeksmalesn = 12

    Exercise and Empagliflozin Each Attenuate Cardiac Injury in Diabetic Cardiomyopathy via Suppression of Inflammation and Modulation of Ferroptosis, without Synergistic Benefit

    Frontiers in endocrinology

  2. Empagliflozin decreases inflammation in mouse cells (IL-1β-stimulated chondrocytes).

    “EMP promoted anabolism, inhibited the inflammatory response and catabolism in IL-1β stimulated chondrocytes.”

    CellsIL-1β-stimulated chondrocyteschondrocyte

    Empagliflozin Alleviates Osteoarthritis Progression by Attenuating Inflammation, Restoring Impaired Autophagy, and Ameliorating Chondrocyte Senescence

    Biomedicines

  3. Empagliflozin decreases inflammation in mice (isoprenaline-induced HFpEF model).

    “Empagliflozin lowered resting flow, normalized CFR, reduced endothelial permeability and inflammatory signaling”

    Animalsisoprenaline-induced HFpEF modeldays 7–21

    Early development and SGLT2 inhibitor-mediated reversal of coronary microvascular dysfunction in an isoprenaline-induced murine HFpEF model: Insights from multimodal in vivo imaging

    International journal of cardiology

  4. Empagliflozin decreases inflammation in rats (post-cardiac arrest).

    “both empagliflozin and BHB treatment attenuated microglial activation”

    Animalspost-cardiac arrestmales

    Empagliflozin Attenuates Global Cerebral Ischemic Injury After Cardiac Arrest Through Enhancing Ketone Body Oxidative Metabolism in Rats

    Journal of the American Heart Association

  5. Empagliflozin decreases inflammation in mouse models of HF induced by transverse aortic constriction.

    “Empagliflozin decreased cardiac C-C chemokine receptor type 2-positive macrophages, suggesting attenuated inflammation.”

    Animalsin mouse models of HF induced by transverse aortic constriction2 weeks

    Empagliflozin Attenuates Cardiac Fibrosis by Suppressing Fibroblast-Mediated C-C Motif Chemokine Ligand 2 Expression

    Journal of the American Heart Association

  6. Empagliflozin decreases inflammation in rats (combined with trandolapril in Ren-2 transgenic rats).

    “attenuated inflammation (leptin, MCP-1, TNFα) and steatotic gene markers”

    Animalscombined with trandolapril in Ren-2 transgenic ratsmales

    Empagliflozin in combination with trandolapril but not with triple therapy improves glucose and lipid metabolism in non-diabetic hypertensive model

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

  7. Empagliflozin decreases inflammation in mice (mouse models of Parkinson’s disease).

    “empagliflozin has demonstrated the ability to improve motor functions, lower neuroinflammation, and promote neuroplasticity in mouse models of Parkinson’s disease.”

    Reviewmouse models of Parkinson’s disease

    POTENTIAL EFFECTS OF SGLT-2 INHIBITORS ON PARKINSON DISEASE

    TOGÜ Sağlık Bilimleri Dergisi

  8. Empagliflozin decreases inflammation in rats (doxorubicin-induced nephrotoxicity).

    “Collectively, antioxidant, anti-inflammatory, and antiapoptotic influences contributed to the preservative potential of EMPA against DOX-induced kidney toxicity.”

    Animalsdoxorubicin-induced nephrotoxicitykidney10 mg/kg/d12 daysmales

    Empagliflozin mitigates doxorubicin-induced nephrotoxicity by modulating sirtuin 1, nuclear factor-κB/tumor necrosis factor-α, and cleaved caspase-3 pathways without compromising its cytotoxic efficacy

    The Journal of pharmacology and experimental therapeutics

  9. Empagliflozin decreases inflammation in O. cuniculus (carrageenan-induced ocular inflammation).

    “The silicon dioxide-loaded film (EMA3) showed significantly lowered intraocular pressure and promising ocular anti-inflammation”

    Animalscarrageenan-induced ocular inflammationsilicon dioxide-loaded HPMC ocular film (EMA3)eye

    Hypotension and antiphlogistic potential of empagliflozin ocular film: swelling and release kinetics

    ADMET & DMPK

  10. Empagliflozin decreases inflammation in human cells (high-glucose exposure (33 mM) in AC16 cells).

    “Empagliflozin reversed high-glucose mediated alterations at the transcriptional level, decreasing inflammatory, metabolic, and aging signatures.”

    Cellshigh-glucose exposure (33 mM) in AC16 cellscardiomyocyte2 and 7 days

    Unlocking the power of empagliflozin: Rescuing inflammation in hyperglycaemia-exposed human cardiomyocytes through comprehensive multi-level analysis

    European journal of heart failure

All 17

More on Inflammation

Cellular senescence

downin mice5downin human cells2downin mouse cells2downin pig cells2+3

13 studies
  1. Empagliflozin decreases cellular senescence in mouse cells.

    “EMP enhanced autophagic activity and attenuated senescent phenotype in vitro.”

    Cellschondrocyte

    Empagliflozin Alleviates Osteoarthritis Progression by Attenuating Inflammation, Restoring Impaired Autophagy, and Ameliorating Chondrocyte Senescence

    Biomedicines

  2. Empagliflozin increases cellular senescence in distal tubular cells, with CDKN2A and CDKN1A co-upregulation.

    “Twenty-four weeks post-cessation, these cells exhibited senescence with co-upregulation of CDKN2A and CDKN1A, EMT progression, and renal interstitial fibrosis.”

    Animalsin distal tubular cells, with CDKN2A and CDKN1A co-upregulationdistal tubular cell24 weeks post-cessation

    SGLT2i-Triggered hyperglycosuria Unveils CDKN2A-Driven distal tubular senescence and EMT, Fueling renal fibrosis

    Biochemical pharmacology

  3. Empagliflozin decreases cellular senescence in mice (natural aging, male C57 mice, versus vehicle).

    “in Old-EMPA group, the expression of P16 and SA-β-gal were downregulated compared to Old-vehicle group”

    Animalsnatural aging, male C57 mice, versus vehiclekidneymales

    Empagliflozin slows down natural kidney senescence via Six1/Wnt4/NF-κB pathway

    Biogerontology

  4. Empagliflozin decreases cellular senescence in HFpEF mice fed high-fat diet with L-NAME.

    “EMPA treatment suppressed the increase in the levels of aging markers (p16 and p21) in HFpEF hearts.”

    Animalsin HFpEF mice fed high-fat diet with L-NAMEheart4 weeks

    Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis

    Cardiovascular diabetology

  5. Empagliflozin decreases cellular senescence in mice with peritoneal dialysis.

    “p53, p21, and p16 increased in mice with PD compared with those in the control group; however, these changes were decreased by empagliflozin.”

    Animalsin mice with peritoneal dialysisparietal peritoneummales

    Empagliflozin attenuates epithelial-to-mesenchymal transition through senescence in peritoneal dialysis

    American journal of physiology. Renal physiology

  6. Empagliflozin decreases cellular senescence in human cells (glucose-treated HPMCs).

    “Reactive oxygen species production, DNA damage, senescence, and EMT markers were increased by glucose treatment; however, cotreatment with glucose and empagliflozin attenuated these changes.”

    Cellsglucose-treated HPMCs

    Empagliflozin attenuates epithelial-to-mesenchymal transition through senescence in peritoneal dialysis

    American journal of physiology. Renal physiology

  7. Empagliflozin decreases cellular senescence in naturally aged mice.

    “downregulated the hepatic protein expression of P21, P16, α-SMA, and COL1A1”

    Animalsin naturally aged miceliver

    Empagliflozin rescues lifespan and liver senescence in naturally aged mice

    GeroScience

  8. Empagliflozin decreases cellular senescence in diabetic nephropathy mice, bioinformatic analysis.

    “This finding indicated that empagliflozin may inhibit the progression of diabetic nephropathy by inhibiting inflammation, apoptosis, and senescence.”

    Animalsin diabetic nephropathy mice, bioinformatic analysis

    RNA-Seq Analysis of ceRNA-Related Networks in the Regulatory Metabolic Pathway of Mice with Diabetic Nephropathy Subjected to Empagliflozin Intervention

    Archivos espanoles de urologia

  9. Empagliflozin decreases cellular senescence in human cells (ponatinib-induced endothelial toxicity) (4 ± 1 versus 9 ± 4 β-Gal+ cells/field).

    “EMPA and DAPA also reversed the effects of PON on cell senescence”

    Cellsponatinib-induced endothelial toxicityhuman aortic endothelial cells500 nmol/L

    Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy

    Vascular pharmacology

  10. Empagliflozin decreases cellular senescence in hHTG rats fed standard diet.

    “along with reduction of markers of inflammation, oxidative stress and cell senescence”

    Animalsin hHTG rats fed standard dietliver, adipose tissue and kidneysix weeksmales

    Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress

    International journal of molecular sciences

All 14

More on Cellular senescence

Oxidative stress and ROS signaling

downin rats6downin mice3downin humans1downin pig cells1+1

12 studies
  1. Empagliflozin decreases oxidative stress and ROS signaling in humans (Lower TOS and OSI and higher TAS at both follow-up visits; all p < 0.001).

    “The exploratory mixed-effects models showed lower TOS and OSI and higher TAS in the study group at both follow-up visits (all p < 0.001).”

    Human trialHeart failure and predominantly obstructive sleep apnea; CPAP initiated in both groups after month 310 mg daily3 and 6 monthsn = 70

    Empagliflozin linked to milder sleep apnea in heart failure

    Antioxidants (Basel, Switzerland)

  2. Empagliflozin decreases oxidative stress and ROS signaling.

    “including modulation of AMPK signaling, attenuation of oxidative stress, and suppression of inflammatory activation.”

    ReviewEvidence predominantly from experimental cardiovascular or metabolic disease models, rather than physiological aging studies

    Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways

    Frontiers in pharmacology

  3. Empagliflozin decreases oxidative stress and ROS signaling in mice (ATO-treated).

    “EMPA treatment effectively inhibits ATO-induced oxidative stress and reduces apoptosis.”

    AnimalsATO-treated

    Empagliflozin Alleviates Arsenic Trioxide-Induced Nephrotoxicity by Activating the SIRT1/Akt/Nrf2 Pathway

    Journal of toxicology

  4. Empagliflozin decreases oxidative stress and ROS signaling in MPTP-induced PD Sirtuin3 knock-out animals.

    “EMPA treatment further reduced the oxidative stress and neurotoxicity through the modulation of glutathione (GSH) system and reduction of 3-hydroxykynurenine (3OHK) in Sirtuin3 knock-out (S3KO) animals.”

    Animalsin MPTP-induced PD Sirtuin3 knock-out animalsstriatum

    Targeted metabolomics to assess positive effects of empagliflozin in a Parkinson's disease model – focused on the kynurenine pathway and oxidative stress

    Research SquarePreprint

  5. Empagliflozin decreases oxidative stress and ROS signaling in rats (doxorubicin-induced nephrotoxicity).

    “EMPA mitigated oxidative stress in renal tissues, as presented by a reduction in malondialdehyde and an increase in both reduced glutathione and superoxide dismutase.”

    Animalsdoxorubicin-induced nephrotoxicitykidney10 mg/kg/d12 daysmales

    Empagliflozin mitigates doxorubicin-induced nephrotoxicity by modulating sirtuin 1, nuclear factor-κB/tumor necrosis factor-α, and cleaved caspase-3 pathways without compromising its cytotoxic efficacy

    The Journal of pharmacology and experimental therapeutics

  6. Empagliflozin decreases oxidative stress and ROS signaling in HFD/STZ-treated diabetic rats.

    “EMPA treatment decreased oxidative stress”

    Animalsin HFD/STZ-treated diabetic ratsheart10 mg/kgeight weeksmales

    Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway

    Journal of food and drug analysis

  7. Empagliflozin decreases oxidative stress and ROS signaling in rat renal ischemia-reperfusion model.

    “Empagliflozin administration significantly reduced creatinine, urea, inflammatory markers, and oxidative stress levels.”

    Animalsin rat renal ischemia-reperfusion modeln = 30

    Investigating the Role of Empagliflozin in the Pathological Progress of Ischemia-Reperfusion Injury in Rat Kidneys: The Involvement of Nitric Oxide

    Advanced pharmaceutical bulletin

  8. Empagliflozin decreases oxidative stress and ROS signaling in rats (doxorubicin-induced cognitive impairment model).

    “attributed to its antioxidant and neuroplasticity-enhancing properties”

    Animalsdoxorubicin-induced cognitive impairment modelbrain10 mg/kg, PO28 days

    Empagliflozin Dampens Doxorubicin-Induced Chemobrain in Rats: The Possible Involvement of Oxidative Stress and PI3K/Akt/mTOR/NF-κB/TNF-α Signaling Pathways

    Molecular neurobiology

  9. Empagliflozin decreases oxidative stress and ROS signaling in hHTG rats fed standard diet.

    “along with reduction of markers of inflammation, oxidative stress and cell senescence”

    Animalsin hHTG rats fed standard dietliver, adipose tissue and kidneysix weeksmales

    Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress

    International journal of molecular sciences

  10. Empagliflozin decreases oxidative stress and ROS signaling in mice (high fructose diet-induced hyperglycemia).

    “EMPA Nps significantly showed reduced levels of inflammatory mediators and oxidative stress.”

    Animalshigh fructose diet-induced hyperglycemiananoparticles

    Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice

    Neurochemistry international

All 12

More on Oxidative stress and ROS signaling

Apoptosis

downin cells2downin mice2downin rats2upin human cells1+1

8 studies
  1. Empagliflozin increases apoptosis in human cells (lung cancer).

    “EMPA altered cell‐cycle progression and increased apoptotic cell death, accompanied by enhanced BAX and CASP3 expression and cleaved caspase‐3 activation.”

    Cellslung cancerA549 and HOP-92 cells

    Empagliflozin Modulates Apoptosis and Autophagy Pathways in Lung Cancer Through Network Pharmacology and In Vitro Analysis

    Journal of biochemical and molecular toxicology

  2. Empagliflozin decreases apoptosis in human cells.

    “serum collected during empagliflozin treatment significantly reduced endothelial cell apoptosis, eEV release, VCAM-1 expression, and mitochondrial reactive oxygen species in vitro”

    Cellsserum collected during treatment, in vitro model of human coronary artery endothelial cellscoronary artery endothelial cell10 mg daily

    Empagliflozin Improves Angina and Endothelial Dysfunction Indices in Angina and No Obstructive Coronary Arteries (ANOCA)

    Arteriosclerosis, thrombosis, and vascular biology

  3. Empagliflozin decreases apoptosis in mice (ATO-treated).

    “reduces apoptosis.”

    AnimalsATO-treated

    Empagliflozin Alleviates Arsenic Trioxide-Induced Nephrotoxicity by Activating the SIRT1/Akt/Nrf2 Pathway

    Journal of toxicology

  4. Empagliflozin decreases apoptosis in rats (doxorubicin-induced nephrotoxicity).

    “Collectively, antioxidant, anti-inflammatory, and antiapoptotic influences contributed to the preservative potential of EMPA against DOX-induced kidney toxicity.”

    Animalsdoxorubicin-induced nephrotoxicitykidney10 mg/kg/d12 daysmales

    Empagliflozin mitigates doxorubicin-induced nephrotoxicity by modulating sirtuin 1, nuclear factor-κB/tumor necrosis factor-α, and cleaved caspase-3 pathways without compromising its cytotoxic efficacy

    The Journal of pharmacology and experimental therapeutics

  5. Empagliflozin inhibits apoptosis in cells (high-glucose and high-uric acid conditions).

    “decreased cleaved caspase-3 levels.”

    Cellshigh-glucose and high-uric acid conditions

    Empagliflozin improves renal injury of diabetic nephropathy complicated with hyperuricemia through AMPK by promoting autophagy and inhibiting apoptosis

    Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

  6. Empagliflozin decreases apoptosis in HFD/STZ-treated diabetic rats.

    “EMPA treatment decreased cardiomyocyte apoptosis”

    Animalsin HFD/STZ-treated diabetic ratsheart10 mg/kgeight weeksmales

    Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway

    Journal of food and drug analysis

  7. Empagliflozin decreases apoptosis in diabetic nephropathy mice, bioinformatic analysis.

    “This finding indicated that empagliflozin may inhibit the progression of diabetic nephropathy by inhibiting inflammation, apoptosis, and senescence.”

    Animalsin diabetic nephropathy mice, bioinformatic analysis

    RNA-Seq Analysis of ceRNA-Related Networks in the Regulatory Metabolic Pathway of Mice with Diabetic Nephropathy Subjected to Empagliflozin Intervention

    Archivos espanoles de urologia

  8. Empagliflozin decreases apoptosis in cells (ethanol-induced injury in H9c2 cells).

    “EMPA pretreatment significantly reduced apoptosis of cardiomyocytes, and reduced the expression of cleaved caspase 3.”

    Cellsethanol-induced injury in H9c2 cells

    Empagliflozin alleviates ethanol-induced cardiomyocyte injury through inhibition of mitochondrial apoptosis via a SIRT1/PTEN/Akt pathway

    Clinical and experimental pharmacology & physiology

More on Apoptosis

Autophagy

upin human cells2upin cells1upin mice1downin mice1+2

7 studies
  1. Empagliflozin increases autophagy in human cells (lung cancer).

    “EMPA increased LC3‐II without p62 accumulation, consistent with increased autophagic activity”

    Cellslung cancerA549 and HOP-92 cells

    Empagliflozin Modulates Apoptosis and Autophagy Pathways in Lung Cancer Through Network Pharmacology and In Vitro Analysis

    Journal of biochemical and molecular toxicology

  2. Empagliflozin increases autophagy in mouse cells.

    “EMP enhanced autophagic activity and attenuated senescent phenotype in vitro.”

    Cellschondrocyte

    Empagliflozin Alleviates Osteoarthritis Progression by Attenuating Inflammation, Restoring Impaired Autophagy, and Ameliorating Chondrocyte Senescence

    Biomedicines

  3. Empagliflozin activates autophagy in cells (high-glucose and high-uric acid conditions).

    “Empagliflozin treatment increased LC3 expression and AMPK phosphorylation”

    Cellshigh-glucose and high-uric acid conditions

    Empagliflozin improves renal injury of diabetic nephropathy complicated with hyperuricemia through AMPK by promoting autophagy and inhibiting apoptosis

    Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

  4. Empagliflozin increases autophagy in mice (co-treatment with ponatinib versus ponatinib alone).

    “showed increased autophagy, decreased Cx43 expression as well as Cx43 lateralization”

    Animalsco-treatment with ponatinib versus ponatinib aloneheart28 daysmales

    Empagliflozin mitigates ponatinib-induced cardiotoxicity by restoring the connexin 43-autophagy pathway

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

  5. Empagliflozin activates autophagy in rotenone-exposed zebrafish.

    “EMP treatment improved DOPAC/DA ratio, Y-Maze task, locomotor activity, expressions of Th and Lcp-1, autophagy and inflammation related (mTor, atg5, tnfα, sirt1, il6, tnfα)”

    Animalsin rotenone-exposed zebrafishbrain30 days

    Sodium-dependent glucose co-transporter-2 inhibitor empagliflozin exerts neuroprotective effects in rotenone-induced Parkinson's disease model in zebrafish; mechanism involving ketogenesis and autophagy

    Brain research

  6. Empagliflozin inhibits autophagy in mice (streptozotocin-induced diabetes) (7.9 ± 0.05 vs. 2.3 ± 0.6 fluorescence intensity/total area).

    “autophagy (7.9 ± 0.05 vs. 2.3 ± 0.6 fluorescence intensity/total area, P < 0.01)”

    Animalsstreptozotocin-induced diabetesheart30 mg/kg/daymales

    Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy

    Cardiovascular research

  7. Empagliflozin induces autophagy in human cells (7 ± 4.3 versus 2.6 ± 2.3 mean fluorescence with vehicle).

    “and induced autophagy (E 500 7 ± 4.3 vs basal DMSO 2.6 ± 2.3 mean fluorescence vs PON 2.6 ± 2.4 mean fluorescence, p < 0.05)”

    Cellshuman aortic endothelial cells500 nmol/L

    Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy

    Vascular pharmacology

More on Autophagy

Cardiac function

upin mice4upin rats2upin zebrafish1

7 studies
  1. Empagliflozin improves cardiac function in zebrafish (Doxorubicin-treated AB zebrafish).

    “Echocardiography showed DOX raised the E/A ratio and myocardial performance index at 28-42 dpi, which both agents attenuated (p<0.05).”

    AnimalsDoxorubicin-treated AB zebrafishHeart6.2 mg/kg daily28–42 days post-injection

    Sodium-Glucose Cotransporter 2 Inhibitors Restore Myocardial Energy Metabolism to Mitigate Doxorubicin Cardiotoxicity in Adult Zebrafish

    AHA Scientific Sessions 2026 abstract

  2. Empagliflozin improves cardiac function in rats (aortic stenosis).

    “Empagliflozin (10 mg/kg/day for 8 weeks) attenuated cardiac dysfunction and reduced HF features.”

    Animalsaortic stenosisheart10 mg/kg/day8 weeks

    Effects of SGLT2 inhibition on cardiac remodeling and heart failure development in aortic stenosis rats

    Molecular biomedicine

  3. Empagliflozin improves cardiac function in mice (myocardial infarction induced by permanent coronary artery ligation).

    “Empagliflozin significantly improved cardiac remodeling and cardiac function in ischemic HF model”

    Animalsmyocardial infarction induced by permanent coronary artery ligationheart10 mg/kg daily3 days before operation until 3 weeks after myocardial infarctionmales

    Empagliflozin attenuates adverse outcomes of acute ischemic heart failure by targeting NLRP3/IL1β mediated macrophage polarization and inflammatory response

    ESC Congress 2026 abstract

  4. Empagliflozin improves cardiac function in rats (ISO-induced myocardial injury).

    “Compared with the model group, empagliflozin improved cardiac function”

    AnimalsISO-induced myocardial injuryheart

    Empagliflozin attenuates ISO-induced myocardial injury through PGC-1α-mediated mitochondrial biogenesis and improved fatty acid metabolism

    Scientific reports

  5. Empagliflozin improves cardiac function in mouse models of HF induced by transverse aortic constriction.

    “Empagliflozin preserved cardiac function and markedly reduced myocardial fibrosis and HF markers.”

    Animalsin mouse models of HF induced by transverse aortic constriction2 weeks

    Empagliflozin Attenuates Cardiac Fibrosis by Suppressing Fibroblast-Mediated C-C Motif Chemokine Ligand 2 Expression

    Journal of the American Heart Association

  6. Empagliflozin improves cardiac function in mice (streptozotocin-induced diabetes).

    “EMPA significantly reversed cardiac dysfunction on echocardiography in diabetic mice”

    Animalsstreptozotocin-induced diabetesheart30 mg/kg/daymales

    Empagliflozin inhibits excessive autophagy through the AMPK/GSK3β signalling pathway in diabetic cardiomyopathy

    Cardiovascular research

  7. Empagliflozin improves cardiac function in mice (streptozotocin-induced diabetes) (P < .01).

    “Empagliflozin also reversed cardiac dysfunction, cardiac fibrosis and cell senescence in mice with (STZ)-induced diabetes (P < .01).”

    Animalsstreptozotocin-induced diabetesheart

    Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes

    Journal of cellular and molecular medicine

HbA1c

downin humans6

6 studies
  1. Empagliflozin decreases HbA1c in humans (Type 2 diabetes mellitus with heart failure; added to standard therapy) (9.02 ± 1.42% to 8.83 ± 1.11%).

    “The HbA1c levels decreased from 9.02 ± 1.42% to 8.83 ± 1.11%, reflecting improved glycemic control following treatment.”

    Human trialType 2 diabetes mellitus with heart failure; added to standard therapy10 to 25mg once a day12 weeksn = 20

    Effect of empagliflozin on adenosine triphosphate levels in vivo in patients with type 2 diabetes mellitus combined with heart failure

    ESC Congress 2026 abstract

  2. Empagliflozin decreases HbA1c in humans (single-arm design, no control group) (9.17% ± 1.24% to 8.36% ± 1.01%).

    “HbA1c (9.17% ± 1.24% to 8.36% ± 1.01%; p < 0.001)”

    Human trialsingle-arm design, no control group10 mg once daily6 months44% malesn = 75

    The Effect of Empagliflozin Treatment on Epicardial Adipose Tissue and Cardiac Function in Patients With Type 2 Diabetes Mellitus

    Echocardiography (Mount Kisco, N.Y.)

  3. Empagliflozin decreases HbA1c in patients with diabetic osteoporosis.

    “After six months of treatment, the intervention group exhibited significantly lower levels of FBG (P < 0.001), 2 h-PG (P = 0.001), and HbA1c (P < 0.001) than the control group.”

    Human trialin patients with diabetic osteoporosis6 monthsn = 100

    The effect of empagliflozin (sodium-glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study

    BMC musculoskeletal disorders

  4. Empagliflozin decreases HbA1c in humans (placebo-adjusted) (-0.57% (95% CI -0.78, -0.36)).

    “The placebo-adjusted mean change from baseline in HbA1c at week 52 with empagliflozin was -0.57% [95% confidence interval (CI) -0.78, -0.36].”

    Human trialplacebo-adjusted10 mg once daily52 weeks

    Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)

    Diabetes, obesity & metabolism

  5. Empagliflozin is linked with lower HbA1c in patients with type 2 diabetes.

    “The empagliflozin group showed significant improvements in HbA1c, fasting plasma glucose, body weight, waist circumference, and fat mass (p < 0.05 for all).”

    Humansin patients with type 2 diabetes6 months

    Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study

    Medicina (Kaunas, Lithuania)

  6. Empagliflozin decreases HbA1c in humans (type 2 diabetes mellitus with established cardiovascular disease) (SMD -0.62, 95% CI -0.95 to -0.30).

    “Our study concluded that empagliflozin significantly reduced HbA1c levels”

    Reviewtype 2 diabetes mellitus with established cardiovascular disease

    Efficacy and safety of SGLT2 inhibitor empagliflozin in T2DM with established cardiovascular disease: a systematic review and meta-analysis of RCTs

    Annals of medicine and surgery (2012)

More on HbA1c

Body weight

downin humans5no changein mice1

6 studies
  1. Empagliflozin decreases body weight in humans (placebo-adjusted) (-2.37 kg (95% CI -3.07, -1.68)).

    “Change in body weight was -3.26 kg and -0.90 kg with empagliflozin and placebo, respectively (placebo-adjusted difference: -2.37 kg; 95% CI -3.07, -1.68).”

    Human trialplacebo-adjusted10 mg once daily52 weeks

    Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)

    Diabetes, obesity & metabolism

  2. Empagliflozin is linked with lower body weight in kidney transplant recipients (2.4 kg average decrease).

    “weight decreased on average 2.4 kg throughout the year”

    Humansin kidney transplant recipientsthroughout the year

    Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases

    Transplantation proceedings

  3. Empagliflozin is linked with lower body weight in humans (compared in non-elderly and elderly subjects).

    “Although the body weight and HbA1c, AST, ALT and γ-GTP levels were significantly reduced in both the non-elderly and elderly subjects”

    Humanscompared in non-elderly and elderly subjectssix monthsn = 110

    Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes

    Diabetes, metabolic syndrome and obesity : targets and therapy

  4. Empagliflozin showed no clear effect on body weight in mice (doxorubicin-treated mice).

    “EMPA neither attenuated nor exacerbated DOX-induced body weight, skeletal muscle, or WAT loss.”

    Animalsdoxorubicin-treated mice10 mg/kg/day6 weeksmalesn = 36

    Empagliflozin does not rescue nor exacerbate doxorubicin-induced skeletal muscle wasting and metabolic dysfunction in male mice

    Scientific reports

  5. Empagliflozin decreases body weight in people without diabetes.

    “In human investigations, EMPA significantly lowered body weight with notable improvements in fasting glucose.”

    Reviewin people without diabetes10-12.5 mg daily

    Empagliflozin in the Absence of Diabetes: A Systematic Review of Its Anthropometric and Metabolic Effects in Humans and Animals

    International journal of endocrinology

  6. Empagliflozin decreases body weight in humans (type 2 diabetes mellitus with established cardiovascular disease) (SMD -2.32, 95% CI -3.42 to -1.21).

    “Additionally, a reduction in body weight was also noted”

    Reviewtype 2 diabetes mellitus with established cardiovascular disease

    Efficacy and safety of SGLT2 inhibitor empagliflozin in T2DM with established cardiovascular disease: a systematic review and meta-analysis of RCTs

    Annals of medicine and surgery (2012)

Adverse events

no changein humans4downin humans1

5 studies
  1. Empagliflozin showed no clear effect on adverse events in humans (ADPKD at high risk of progression; not treated with tolvaptan; compared with placebo).

    “Frequency of adverse events was similar between the 2 groups.”

    Human trialADPKD at high risk of progression; not treated with tolvaptan; compared with placebo25 mg once daily12 monthsn = 50

    Empagliflozin was well tolerated in a kidney disease trial

    Journal of the American Society of Nephrology : JASN

  2. Empagliflozin showed no clear effect on adverse events in humans.

    “Adverse events were minimal and showed no significant differences between the two study arms (P > 0.05).”

    Human trial6 months

    Efficacy of Empagliflozin in Patients with Mild-to-Moderate Ulcerative Colitis: A Randomized Controlled Pilot Study

    Research SquarePreprint

  3. Empagliflozin showed no clear effect on adverse events in humans after heart valve surgery; includes hypoglycemia and infection.

    “No significant differences were observed in postoperative CRP levels (p = 0.12) or adverse event rates, including hypoglycemia and infection.”

    Human trialafter heart valve surgery; includes hypoglycemia and infection10 mg daily3 days pre-op to 3 days post-opn = 81

    Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after heart valve surgery: a double-blind, randomized, placebo-controlled trial

    Indian journal of thoracic and cardiovascular surgery

  4. Empagliflozin decreases adverse events in hospitalized acute heart failure.

    “Frequencies of adverse events were consistently lower with empagliflozin vs placebo.”

    Human trialin hospitalized acute heart failure10 mg/dday 90

    Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE

    JACC. Heart failure

  5. Empagliflozin was not clearly linked with adverse events in humans (added to standard medical therapy in heart failure after acute anterior STEMI).

    “The incidence of adverse events was similar between groups”

    Humansadded to standard medical therapy in heart failure after acute anterior STEMI10 mg once dailyn = 98

    Short-Term Efficacy of Early Sodium-Glucose Cotransporter 2 Inhibitor Initiation in Patients With Heart Failure After Acute Anterior Myocardial Infarction

    Reviews in cardiovascular medicine

Quality of life

upin humans4no changein humans1

5 studies
  1. Empagliflozin showed no clear effect on quality of life in humans (placebo-controlled comparison; exploratory outcome).

    “No significant treatment differences were observed for neither daily physical activity nor QoL.”

    Human trialplacebo-controlled comparison; exploratory outcome180 days

    Empagliflozin and functional aerobic capacity in individuals with increased risk of heart failure: The Empire Prevent Cardiac trial

    American heart journal

  2. Empagliflozin improves quality of life in humans (chronic syndrome of inappropriate antidiuresis following traumatic subarachnoid hemorrhage).

    “This allowed increased fluid intake (1750 mL/day) and improved quality of life.”

    Human trialchronic syndrome of inappropriate antidiuresis following traumatic subarachnoid hemorrhage25 milligrams/day16 monthsfemales

    Long-term Empagliflozin Use in Chronic Syndrome of Inappropriate Antidiuresis Due to Traumatic Subarachnoid Hemorrhage

    JCEM case reports

  3. Empagliflozin is linked with better quality of life in patients with stable heart failure.

    “The GNRI, MNA, KCCQ-12, body mass index, and NT-proBNP levels improved significantly”

    Humansin patients with stable heart failure10 mg daily6 monthsn = 93

    Association between empagliflozin exposure and skeletal muscle degeneration in patients with heart failure

    BMC cardiovascular disorders

  4. Empagliflozin is linked with better quality of life in humans (heart failure) (74.3 ± 19.5 vs. 67.1 ± 19.5, p<0.01).

    “A significant improvement was observed in the KCCQ-12 overall score (74.3 ± 19.5 vs. 67.1 ± 19.5, p<0.01)”

    Humansheart failure24 weeksn = 101

    The effect of empagliflozin on the quality of life in patients with heart failure: results from the Hungarian cohort of the international Emp-Activity study

    Orvosi hetilap

  5. Empagliflozin improves quality of life in humans.

    “improved quality of life measures”

    Review

    Evaluating the Clinical Outcomes of Empagliflozin in Heart Failure Patients With Preserved Ejection Fraction: A Systematic Review

    Cureus

Cognitive function

upin humans2upin rats2upin mice1

5 studies
  1. Empagliflozin improves cognitive function in humans (frail older adults with type 2 diabetes and HFpEF) (Montreal Cognitive Assessment 19.80 to 22.25 after 1 month (P < 0.001)).

    “Montreal Cognitive Assessment scores at baseline and after 1 month were 19.80 ± 3.77 vs. 22.25 ± 3.27 (P < 0.001) in the empagliflozin group”

    Human trialfrail older adults with type 2 diabetes and HFpEF1 month

    Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

    Diabetes care

  2. Empagliflozin is linked with better cognitive function in humans.

    “At 3-month follow-up, we detected a significant improvement in the MoCA score and in the 5mGS in patients receiving empagliflozin compared with non-treated subjects.”

    Humansfrail older adults with diabetes and hypertension, propensity-matched against non-treated patients3 months

    SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients

    Hypertension (Dallas, Tex. : 1979)

  3. Empagliflozin improves cognitive function in rats (AlCl3-induced AD) (4.17-fold).

    “improved locomotor activity (1.86-fold) and cognitive performance (T-maze) (4.17-fold).”

    AnimalsAlCl3-induced AD

    Novel Repurposing of Empagliflozin-Loaded Buccal Composite (Chitosan/Silk Fibroin/Poly(lactic acid)) Nanofibers for Alzheimer's Disease Management via Modulation of Aβ-AGER-p-tau Pathway

    Pharmaceutics

  4. Empagliflozin improves cognitive function in streptozotocin-induced diabetic rats.

    “empagliflozin reversed these changes, improving SOD and CAT activity, GLT content and reducing Nox-4 expression and MDA concentration in brain tissue while improving cognitive ability”

    Animalsin streptozotocin-induced diabetic ratsbrain20 mg/kg oral5 weeksmalesn = 8

    Empagliflozin alleviates diabetes-induced cognitive impairments by lowering nicotinamide adenine dinucleotide phosphate oxidase-4 expression and potentiating the antioxidant defense system in brain tissue of diabetic rats

    Behavioural brain research

  5. Empagliflozin improves cognitive function in high-fat diet plus streptozotocin T2D-AD mice.

    “SGLT2-i and DPP4-i significantly improved hippocampal-dependent learning, memory, and cognitive functions in the T2D-AD mouse model.”

    Animalsin high-fat diet plus streptozotocin T2D-AD mice25 mg/kg/day7 weeks

    SGLT2 and DPP4 inhibitors improve Alzheimer's disease-like pathology and cognitive function through distinct mechanisms in a T2D-AD mouse model

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

NT-proBNP

downin humans3upin humans1

4 studies
  1. Empagliflozin decreases NT-proBNP in humans (Heart failure with reduced ejection fraction and type 2 diabetes or prediabetes).

    “Across the overall study population, uric acid and NT-proBNP decreased and haematocrit increased”

    Human trialHeart failure with reduced ejection fraction and type 2 diabetes or prediabetes36 weeksn = 105

    Empagliflozin reduced heart chamber volumes alongside other drugs

    ESC Congress 2026 abstract

  2. Empagliflozin decreases NT-proBNP in humans.

    “Notably, there were significant improvements in GNRI (p < 0.001), MNA (p < 0.001), KCCQ12-OS (p < 0.01), KCCQ12-CS (p < 0.01), BMI (p = 0.005), and NT-proBNP (p < 0.001).”

    Human trial6 monthsn = 93

    Association between empagliflozin exposure and skeletal muscle degeneration in patients with heart failure

    BMC cardiovascular disorders

  3. Empagliflozin is linked with better NT-proBNP in humans (heart failure, with or without diabetes).

    “and N-terminal pro–B-type Natriuretic Peptide (NT-proBNP) levels (p < 0.001).”

    Humansheart failure, with or without diabetes10 mg dailysix monthsn = 797

    Real-world insights into empagliflozin use in heart failure across ejection fractions and patients with or without diabetes: a multicenter study from Bangladesh

    BMC endocrine disorders

  4. Empagliflozin is linked with lower NT-proBNP in humans (type 2 diabetes and acute decompensated heart failure; compared with basal-bolus insulin) (1699 ± 522 vs. 2303 ± 598 pg/ml at discharge).

    “the N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were lower in the empagliflozin continuation group than in the insulin group”

    Humanstype 2 diabetes and acute decompensated heart failure; compared with basal-bolus insulincombined with basal insulin regimenduring hospitalization

    Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure

    Journal of the American Geriatrics Society

More on NT-proBNP

Left ventricular ejection fraction

upin humans2no changein humans1upin mice1

4 studies
  1. Empagliflozin showed no clear effect on left ventricular ejection fraction in humans (Type 2 diabetes mellitus with heart failure; added to standard therapy).

    “The left ventricular ejection fraction remained relatively stable, with no significant change (p > 0.05).”

    Human trialType 2 diabetes mellitus with heart failure; added to standard therapyheart10 to 25mg once a day12 weeksn = 20

    Effect of empagliflozin on adenosine triphosphate levels in vivo in patients with type 2 diabetes mellitus combined with heart failure

    ESC Congress 2026 abstract

  2. Empagliflozin is linked with higher left ventricular ejection fraction in humans (1.92% (95% CI 0.44-3.40%; p = 0.012)).

    “the SGLT2i group showed a significantly greater improvement in LVEF than the control group”

    Humansadded to standard medical therapy in heart failure after acute anterior STEMI; multivariable-adjustedleft ventricle10 mg once dailyadmission to one month after dischargen = 98

    Short-Term Efficacy of Early Sodium-Glucose Cotransporter 2 Inhibitor Initiation in Patients With Heart Failure After Acute Anterior Myocardial Infarction

    Reviews in cardiovascular medicine

  3. Empagliflozin is linked with better left ventricular ejection fraction in humans (heart failure, with or without diabetes).

    “echocardiographic parameters such as left ventricular ejection fraction (LVEF) (p = 0.003)”

    Humansheart failure, with or without diabetesheart10 mg dailysix monthsn = 797

    Real-world insights into empagliflozin use in heart failure across ejection fractions and patients with or without diabetes: a multicenter study from Bangladesh

    BMC endocrine disorders

  4. Empagliflozin increases left ventricular ejection fraction in mice (Males +9±3%; females +10±2%; both p<0.0001).

    “improved LVEF by 9±3% and 10±2%, respectively (both p<0.0001).”

    AnimalsEstablished pressure-overload left ventricular hypertrophy after transverse aortic constrictionheart30 mg/kg/dayfour weeks

    Empagliflozin promotes reverse remodeling via cardiometabolic reprogramming in established pressure-overload left ventricular hypertrophy

    ESC Congress 2026 abstract

Systolic blood pressure

downin humans3downin rats1

4 studies
  1. Empagliflozin decreases systolic blood pressure in humans.

    “greater reductions in systolic blood pressure were observed with empagliflozin and combination therapy versus finerenone alone at higher baseline BMI”

    Human trialChronic kidney disease and type 2 diabetes; higher baseline BMI; compared with finerenone alone

    Finerenone with empagliflozin according to body mass index in chronic kidney disease and type 2 diabetes

    ESC Congress 2026 abstract

  2. Empagliflozin decreases systolic blood pressure in humans (-8.14 mmHg).

    “At week 12, adjusted mean difference versus placebo in change from baseline in mean 24-h SBP was -8.14 mmHg (95% CI − 10.32, − 3.96, P = 0.005).”

    Human trial12 weeksn = 124

    Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms

    Scientific reports

  3. Empagliflozin decreases systolic blood pressure in hypertensive patients with diabetes (SBP -5.93 mm Hg).

    “largest numerical effect for empagliflozin 25 mg (SBP -5.93 mm Hg)”

    Reviewin hypertensive patients with diabetes25 mg

    Dose-dependent effects of SGLT2 inhibitors on circadian blood pressure in hypertensive patients with diabetes: A systematic review and Bayesian network meta-analysis

    International journal of cardiology. Cardiovascular risk and prevention

  4. Empagliflozin decreases systolic blood pressure in rats (obese ZSF1 rats).

    “These effects were prevented by the empa treatment.”

    Animalsobese ZSF1 rats30 mg/kg/day6 weeks

    Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat

    Cardiovascular diabetology

Frailty

no changein humans2downin humans1

3 studies
  1. Empagliflozin showed no clear effect on frailty in humans.

    “In contrast, there was no significant change in the CONUT score, Barthel index, or clinical frailty score.”

    Human trial6 monthsn = 93

    Association between empagliflozin exposure and skeletal muscle degeneration in patients with heart failure

    BMC cardiovascular disorders

  2. Empagliflozin decreases frailty in humans (at Week 12) (odds ratio: 1.12 [95% confidence interval, CI, 1.01–1.24]).

    “Compared with placebo, empagliflozin patients had a higher likelihood of being in a lower FI category at Weeks 12, 32 and 52, odds ratio: 1.12 [95% confidence interval, CI, 1.01–1.24], 1.21 [1.09–1.34] and 1.20 [1.09–1.33] at Week 12, 32 and 52; P = 0.030, <0.001 and <0.001, respectively.”

    Human trialat Week 12median of 26 monthsn = 5,988

    Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved

    Journal of cachexia, sarcopenia and muscle

  3. Empagliflozin was not clearly linked with frailty in patients with stable heart failure.

    “whereas the CONUT, Barthel index, and frailty scores remained unchanged”

    Humansin patients with stable heart failure10 mg daily6 monthsn = 93

    Association between empagliflozin exposure and skeletal muscle degeneration in patients with heart failure

    BMC cardiovascular disorders

  4. Empagliflozin was not clearly linked with frailty in humans (over approximately six months, in older adults with type 2 diabetes).

    “Neither drug negatively affected frailty, cognition, physical performance, or sleep.”

    Humansover approximately six months, in older adults with type 2 diabetesapproximately six monthsn = 20

    Differential effects of dapagliflozin and empagliflozin on skeletal muscle mass in older adults with type 2 diabetes

    Endocrine

All 451

What is empagliflozin linked with?

80

Studies link empagliflozin with 80 measures, most often mortality (6 studies), major adverse cardiovascular events (4) and dementia (3).

Mortality

downin humans6RR 0.73

6 studies
  1. Empagliflozin lowers the risk of mortality in humans (compared with placebo, network meta-analysis) (OR 0.69 (95% CI 0.62-0.76)).

    “sotagliflozin (OR 0.50; 95% CI: 0.40-0.63;p-score=0.98), empagliflozin (OR 0.69; 95% CI 0.62-0.76; p-score=0.88), and metformin (OR 0.79; 95% CI 0.35-1.75; p-score=0.63) had lowest odds of mortality”

    Human trialcompared with placebo, network meta-analysis

    Comparative Efficacy of Obesity Treatments on Major Adverse Cardiovascular Events, Heart Failure, and All-Cause Mortality in Adults with Overweight and Obesity: A Systematic Review and Network Meta-analysis

    ADA Scientific Sessions 2026 abstract

  2. Empagliflozin is linked with a lower risk of mortality in humans (early initiation (during HHF or 0-7 days post-discharge) versus delayed or no initiation) (RR 0.73, 95% CI 0.69-0.78; 1-year absolute mortality 24.7% early vs 33.6% delayed or no initiation).

    “early and intermediate empagliflozin initiation were associated with lower 1-year post-discharge all-cause mortality than delayed or no initiation (risk ratio [RR] 0.73, 95% confidence interval [CI]: 0.69-0.78”

    Humansearly initiation (during HHF or 0-7 days post-discharge) versus delayed or no initiation1 year post-dischargen = 99,738

    Early versus delayed or no empagliflozin initiation after hospitalisation for heart failure in the United States: A target trial emulation

    ESC heart failure

  3. Empagliflozin is linked with a lower risk of mortality in humans (compared with DPP4 inhibitors) (HR 0.66 [0.57, 0.76]; IRD -8.6 (-11.4, -5.8)).

    “ACM (HR 0.66 [0.57, 0.76]; IRD = -8.6 [-11.4, -5.8])”

    Humanscompared with DPP4 inhibitors

    Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study

    Diabetes care

  4. Empagliflozin is linked with a lower risk of mortality in humans (type 2 diabetes) (adjusted HR 0.76, 95% CI 0.69 to 0.83).

    “all-cause mortality occurred in 551 out of 13,239 (4.2%) in the empagliflozin group and 6,589 out of 49,264 (13.4%) in the active control group (adjusted HR 0.76, 95% CI 0.69 to 0.83)”

    Humanstype 2 diabetesn = 49,264

    Enhancing evidence-based care using trial emulation in electronic health records: real-world effects of empagliflozin in people with type 2 diabetes

    BMJ open diabetes research & care

  5. Empagliflozin is linked with a lower risk of mortality in humans (heart failure with mildly reduced ejection fraction (LVEF 41-49%)) (HR 0.75, 95% CI 0.59-0.96).

    “empagliflozin was associated with lower all-cause mortality (HR 0.75, 95% CI 0.59-0.96)”

    Humansheart failure with mildly reduced ejection fraction (LVEF 41-49%)1 year

    Differential Outcomes with Empagliflozin and Dapagliflozin in Heart Failure with Mildly Reduced Ejection Fraction

    medRxiv : the preprint server for health sciencesPreprint

  6. Empagliflozin is linked with a lower risk of mortality in humans (vs DPP4i, propensity-matched Medicare cohort) (HR=0.66 (0.60, 0.72); RD= -8.48 (-10.14, -6.82)).

    “and mortality [HR=0.66 (0.60, 0.72); RD= -8.48 (-10.14, -6.82)] vs DPP4i”

    Humansvs DPP4i, propensity-matched Medicare cohort

    Comparative Effectiveness of Empagliflozin vs. DPP-4i on MACE, HHF, and Mortality across Demographic Factors

    ADA Scientific Sessions 2025 abstract

Major adverse cardiovascular events

downin humans4HR 0.68–0.77

4 studies
  1. Empagliflozin is linked with a lower risk of major adverse cardiovascular events in humans (compared with DPP4 inhibitors) (HR 0.77, 99.9% CI 0.69–0.85; IRD -10.3 (-14.1, -6.4)).

    “Empagliflozin was associated with decreased risk of MACE (HR 0.77, 99.9% CI [0.69, 0.85]”

    Humanscompared with DPP4 inhibitors

    Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study

    Diabetes care

  2. Empagliflozin is linked with a lower risk of major adverse cardiovascular events in humans (vs DPP4i, propensity-matched Medicare cohort) (HR=0.77 (0.72, 0.81); RD= -10.10 (-12.38, -7.83)).

    “EMPA was associated with decreased risk of MACE [HR=0.77 (0.72, 0.81); RD= -10.10 (-12.38, -7.83)]”

    Humansvs DPP4i, propensity-matched Medicare cohort

    Comparative Effectiveness of Empagliflozin vs. DPP-4i on MACE, HHF, and Mortality across Demographic Factors

    ADA Scientific Sessions 2025 abstract

  3. Empagliflozin is linked with a lower risk of major adverse cardiovascular events in humans (compared with DPP-4i) (HR 0.73 [0.62, 0.86]; RD -6.37 per 1000 person-years).

    “MACE (HR 0.73 [0.62, 0.86]; RD -6.37 [-8.98, -3.77])”

    Humanscompared with DPP-4in = 115,116

    Effectiveness and safety of empagliflozin: final results from the EMPRISE study

    Diabetologia

  4. Empagliflozin is linked with a lower risk of major adverse cardiovascular events in humans (relative to sitagliptin, Medicare beneficiaries with type 2 diabetes) (HR 0.68 (95% CI 0.60-0.77)).

    “Compared with sitagliptin, empagliflozin was associated with reduced risks of the modified MACE outcome (HR, 0.68; 95% CI, 0.60-0.77)”

    Humansrelative to sitagliptin, Medicare beneficiaries with type 2 diabetesn = 45,624

    Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics

    JAMA network open

More on Major adverse cardiovascular events

Dementia

downin humans3HR 0.59–0.69

3 studies
  1. Empagliflozin is linked with a lower risk of dementia in humans (propensity score-matched cohort of older adults with heart failure, EHR data) (HR 0.59, 95% CI 0.52–0.67).

    “Empagliflozin use was associated with significantly reduced risk of AD (HR 0.61, 95% CI 0.48–0.77, p<0.001), VD (HR 0.56, 95% CI 0.44–0.71, p<0.001), unspecified dementia (HR 0.59, 95% CI 0.52–0.67, p<0.001)”

    Humanspropensity score-matched cohort of older adults with heart failure, EHR data2-year follow-upn = 32,761

    Sodium-Glucose Cotransporter-2 Inhibitor Use Is Associated with Improved Cognitive Outcomes in Older Heart Failure Patients: A Comparative Analysis Using Real-World Clinical Data

    AHA Scientific Sessions 2025 abstract

  2. Empagliflozin is linked with a lower risk of dementia in humans (compared with DPP-4 inhibitors) (aHR 0.78 (95% CI 0.69-0.89)).

    “followed by empagliflozin (aHR 0.78 [95% CI 0.69-0.89])”

    Humanscompared with DPP-4 inhibitorsmean follow-up 2.80 years

    Association of Sodium-Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study

    Diabetes care

  3. Empagliflozin lowers the risk of dementia in humans (network meta-analysis versus other antidiabetic medications or placebo) (HR 0.69, 95% CrI 0.55–0.85; highest probability of being ranked most effective (81.2%)).

    “and Empagliflozin (HR = 0.69, 95% CrI: 0.55, 0.85) significantly reduced the risk of dementia onset.”

    Reviewnetwork meta-analysis versus other antidiabetic medications or placebo

    Association between different sodium-glucose co-transporter 2 inhibitors and the risk of dementia: a network meta-analysis

    Frontiers in endocrinology

More on Dementia

Hospitalization for heart failure

downin humans2RR 0.54–0.75

2 studies
  1. Empagliflozin lowers the risk of hospitalization for heart failure in humans (Prediabetes and heart failure; compared with placebo) (RR 0.75, 95% CI 0.60–0.93, p = 0.010).

    “empagliflozin (RR 0.75, 95% CI 0.60–0.93, p = 0.010) in patients with prediabetes and heart failure.”

    ReviewPrediabetes and heart failure; compared with placebo

    Cardiovascular Effects of a Broad Range of Interventions for Adults with Prediabetes: A Systematic Review of Randomized Controlled Trials

    Medical sciences (Basel, Switzerland)

  2. Empagliflozin lowers the risk of hospitalization for heart failure in humans (Heart failure with mildly reduced or preserved ejection fraction; compared with exenatide) (RR 0.54, 95% CI 0.34-0.86).

    “empagliflozin (RR 0.54, 95% CI 0.34-0.86), and semaglutide (RR 0.43, 95% CI 0.20-0.91) were related to decreased risk of HF hospitalization.”

    ReviewHeart failure with mildly reduced or preserved ejection fraction; compared with exenatide

    Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials

    Drugs

Major adverse cardiovascular events

upin humans1downin humans1RR 1.55

2 studies
  1. Empagliflozin is associated with major adverse cardiovascular events in humans (ACS and multivessel coronary disease; compared with dapagliflozin) (RR 1.55, 95% CI 0.93–2.59; P = 0.094).

    “empagliflozin versus dapagliflozin had an RR of 1.55 (95% CI, 0.93–2.59; P = 0.094)”

    HumansACS and multivessel coronary disease; compared with dapagliflozin3 monthsn = 277

    Guideline-directed discharge medication patterns and post-discharge outcomes in older patients with acute coronary syndrome and multivessel coronary disease: A real-world observational study

    PloS one

  2. Empagliflozin is linked with a lower risk of major adverse cardiovascular events in humans (compared with GLP-1RA after propensity score matching) (HR 0.90 (0.82, 0.99); RD -2.54 (-4.76, -0.32) per 1,000 person-years).

    “MACE [HR: 0.90 (0.82, 0.99); RD: -2.54 (-4.76, -0.32)]”

    Humanscompared with GLP-1RA after propensity score matchingn = 141,541

    Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study

    Cardiovascular diabetology

Emphysematous cystitis

upin humans2

2 studies
  1. Empagliflozin is associated with emphysematous cystitis in a patient with type 2 diabetes.

    “We present a unique case of this gas-forming infection in a man with type 2 diabetes mellitus (T2DM) treated with empagliflozin.”

    Humansin a patient with type 2 diabetesurinary bladderfour months after initiationmalesn = 1

    Emphysematous Cystitis and Urinary Retention in a Male Patient With Diabetes Mellitus Type 2 Treated With Empagliflozin

    AACE clinical case reports

  2. Empagliflozin is associated with emphysematous cystitis in humans (published case reports; causality remains uncertain).

    “Empagliflozin-associated emphysematous cystitis is a rare but serious condition mostly seen in elderly patients with multiple health issues and urinary tract abnormalities.”

    Reviewpublished case reports; causality remains uncertainurinary bladdern = 7

    Empagliflozin-associated emphysematous cystitis: a systematic review of published case reports

    Review of Clinical Pharmacology and Pharmacokinetics - International Edition

More on Emphysematous cystitis

All-cause hospitalization

downin humans2RR 0.91

2 studies
  1. Empagliflozin lowers the risk of all-cause hospitalization in patients with CKD (HR 0.86 (95% CI 0.78 to 0.95); 14% relative risk reduction).

    “and all-cause hospitalization by 14% (hazard ratio, 0.86; 95% confidence interval, 0.78 to 0.95)”

    Human trialin patients with CKD10 mg daily2 years (median)n = 6,609

    Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial

    Clinical journal of the American Society of Nephrology : CJASN

  2. Empagliflozin is linked with a lower risk of all-cause hospitalization in humans (early initiation (during HHF or 0-7 days post-discharge) versus delayed or no initiation) (RR 0.91, 95% CI 0.88-0.94).

    “and all-cause hospitalisations (RR 0.91, 95% CI: 0.88-0.94)”

    Humansearly initiation (during HHF or 0-7 days post-discharge) versus delayed or no initiation1 year post-dischargen = 99,738

    Early versus delayed or no empagliflozin initiation after hospitalisation for heart failure in the United States: A target trial emulation

    ESC heart failure

Heart failure

downin humans2HR 0.64–0.72

2 studies
  1. Empagliflozin is linked with a lower risk of heart failure in humans (heart failure with mildly reduced ejection fraction (LVEF 41-49%)) (HR 0.64, 95% CI 0.57-0.73).

    “and HF exacerbations (HR 0.64, 95% CI 0.57-0.73) compared to dapagliflozin”

    Humansheart failure with mildly reduced ejection fraction (LVEF 41-49%)1 year

    Differential Outcomes with Empagliflozin and Dapagliflozin in Heart Failure with Mildly Reduced Ejection Fraction

    medRxiv : the preprint server for health sciencesPreprint

  2. Empagliflozin is linked with a lower risk of heart failure in humans (vs DPP4i, propensity-matched Medicare cohort) (HR=0.72 (0.69, 0.76); RD= -17.68 (-20.45, -14.91)).

    “HHF [HR=0.72 (0.69, 0.76); RD= -17.68 (-20.45, -14.91)]”

    Humansvs DPP4i, propensity-matched Medicare cohort

    Comparative Effectiveness of Empagliflozin vs. DPP-4i on MACE, HHF, and Mortality across Demographic Factors

    ADA Scientific Sessions 2025 abstract

More on Heart failure

Hospitalization

downin humans2HR 0.61–0.86

2 studies
  1. Empagliflozin lowers the risk of hospitalization in humans (HR, 0.86; 95% CI, 0.78 to 0.95).

    “Overall, there was a 14% reduction in total all-cause hospitalizations in participants allocated to empagliflozin versus placebo (HR, 0.86; 95% CI, 0.78 to 0.95), which was not clearly driven by a single cause of hospitalization (see previous reports).”

    Human trialmedian 2.0 yearsn = 6,609

    Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial

    Clinical journal of the American Society of Nephrology : CJASN

  2. Empagliflozin is linked with a lower risk of hospitalization in humans (heart failure with mildly reduced ejection fraction (LVEF 41-49%)) (HR 0.61, 95% CI 0.55-0.67).

    “substantially fewer hospitalizations (HR 0.61, 95% CI 0.55-0.67)”

    Humansheart failure with mildly reduced ejection fraction (LVEF 41-49%)1 year

    Differential Outcomes with Empagliflozin and Dapagliflozin in Heart Failure with Mildly Reduced Ejection Fraction

    medRxiv : the preprint server for health sciencesPreprint

Estimated glomerular filtration rate

upin humans1no changein humans1

2 studies
  1. Empagliflozin is associated with estimated glomerular filtration rate in humans (type 2 diabetes and stage 3 chronic kidney disease) (+2.75 mL/min/1.73m2 at 6 months).

    “Overall, eGFR increased by 2.75 mL/min/1.73m2 at 6 months (p < 0.0001)”

    Humanstype 2 diabetes and stage 3 chronic kidney disease6 monthsn = 166

    The eGFR Slope After Starting Therapy with Empagliflozin in a Cohort of Patients with Diabetes and Stage 3 CKD: Is It Really an Issue? TEMPOREALE Real-World Study

    Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia

  2. Empagliflozin is associated with estimated glomerular filtration rate in humans after rechallenge in CKD stage 4 (22–25 mL/min/1.73m2 over 12 months).

    “Over 12 months, eGFR remained stable (22–25), and there were no further DKA episodes.”

    Humansafter rechallenge in CKD stage 4kidney10 mg/dayover 12 monthsfemalesn = 1

    Paradoxical Renal Protection after Euglycemic DKA in a CKD Stage 4 Diabetic Patient on Empagliflozin: A Case Report and Mechanistic Insights

    AHA Scientific Sessions 2025 abstract

More on Estimated glomerular filtration rate

Cardiovascular death or HF hospitalization

downin humans2

2 studies
  1. Empagliflozin lowers the risk of cardiovascular death or HF hospitalization in humans (irrespective of baseline IGFBP7 tertile).

    “Empagliflozin reduced risk for cardiovascular death/HF hospitalization irrespective of baseline IGFBP7”

    Human trialirrespective of baseline IGFBP7 tertile

    Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme

    European journal of heart failure

  2. Empagliflozin lowers the risk of cardiovascular death or HF hospitalization in humans.

    “Empagliflozin also reduced the primary endpoint compared with placebo across the spectrum of patient age taken as a continuous variable (p for interaction = 0.24; online supplementary Figure ).”

    Human trial52 weeksn = 3,730

    Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced

    European journal of heart failure

Kidney disease progression or cardiovascular death

downin humans1HR 0.72

1 study
  1. Empagliflozin lowers the risk of kidney disease progression or cardiovascular death in patients with CKD (HR 0.72 (95% CI 0.64 to 0.82); 28% relative risk reduction).

    “allocation to empagliflozin reduced the risk of the primary outcome of kidney disease progression or cardiovascular death by 28% (hazard ratio, 0.72; 95% confidence interval, 0.64 to 0.82)”

    Human trialin patients with CKD10 mg daily2 years (median)n = 6,609

    Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial

    Clinical journal of the American Society of Nephrology : CJASN

  2. Empagliflozin lowers the risk of kidney disease progression or cardiovascular death in humans (HR, 0.72; 95% CI, 0.64 to 0.82).

    “Overall, versus placebo, empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death by 28% (HR, 0.72; 95% CI, 0.64 to 0.82”

    Human trialmedian 2.0 yearsn = 6,609

    Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial

    Clinical journal of the American Society of Nephrology : CJASN

More on Kidney disease progression or cardiovascular death

Cardiovascular death or heart failure hospitalization

downin humans1HR 0.59

1 study
  1. Empagliflozin lowers the risk of cardiovascular death or heart failure hospitalization in humans (HR for non-frail group shown; severe frailty HR 0.90 (0.69-1.16) not significant) (HR 0.59 (95% CI 0.42-0.83) in non-frail; 0.90 (0.69-1.16) in severe frailty).

    “Compared with placebo, empagliflozin reduced the risk for the primary outcome across the four FI categories”

    Human trialHR for non-frail group shown; severe frailty HR 0.90 (0.69-1.16) not significant

    Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved

    Journal of cachexia, sarcopenia and muscle

  2. Empagliflozin lowers the risk of cardiovascular death or heart failure hospitalization in humans (non-frail group) (HR 0.59 (0.42, 0.83)).

    “Major adverse clinical outcomes of the EMPEROR‐Preserved trial were more likely in more severely frail patients, and the hazard ratio of primary outcome (time to first event of CV death or HHF) by empagliflozin treatment was 0.59 (0.42, 0.83), 0.79 (0.61, 1.01), 0.77 (0.61, 0.96) and 0.90 (0.69, 1.16) in the non‐frail, mild frailty, moderate frailty and severe frailty groups, respectively (P trend = 0.097”

    Human trialnon-frail groupmedian of 26 monthsn = 1,514

    Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved

    Journal of cachexia, sarcopenia and muscle

Serum electrolytes

mixedin humans1

1 study
  1. Empagliflozin is associated with serum electrolytes in humans (Ambulatory heart failure; compared with placebo) (Sodium and chloride each +0.1 mmol/L; bicarbonate −0.2 mmol/L on average).

    “empagliflozin slightly increased Na+ and Cl− by + 0.1 mmol/L on average, particularly from week 32 onwards (P < 0.05), while reducing serum bicarbonate levels”

    Human trialAmbulatory heart failure; compared with placebo

    Lower blood chloride linked to worse heart failure outcomes

    Clinical research in cardiology : official journal of the German Cardiac Society

More on Serum electrolytes

Liver stiffness

downin humans1

1 study
  1. Empagliflozin is associated with liver stiffness in humans (T2DM and MASLD; single-arm pre–post comparison) (LSM: 7.22 ± 1.04 to 6.24 ± 0.41).

    “12 weeks of empagliflozin treatment was associated with significant reductions in liver enzyme levels, hepatic steatosis, and liver stiffness”

    Human trialT2DM and MASLD; single-arm pre–post comparisonliver25 mg/day12 weeksn = 30

    Changes in liver steatosis and liver stiffness following Empagliflozin treatment in patients with <scp>MASLD</scp> and type 2 diabetes: A single‐arm pre–post study

    Journal of diabetes investigation

All 80

Has empagliflozin been tested in people?

80 of 298 about aging

Yes: 94 trials and 117 observational studies in people have been published, and 281 trials are registered.

Approved

  • EMA Jardiance

    May 22, 2014Diabetes Mellitus, Type 2, Heart Failure, Renal Insufficiency, Chronic, Chronic Heart Failure, Chronic Kidney Disease

  • FDA Jardiance

    Aug 1, 2014Diabetes Mellitus, Type 2, Heart Failure, Chronic Kidney Disease, End Stage Kidney Disease, established cardiovascular disease

Repurposing

40 of 96

Every condition in trials

  • Autosomal dominant polycystic kidney

    Phase 4Active, not recruiting3 trials

  • Motor Activity

    Phase 4Completed2 trials

  • TYPE2 diabetes

    Phase 4Status unknown2 trials

  • Diabetes Mellitus, Insulin-Resistant, with Acanthosis Nigricans

    Phase 3Status unknown2 trials

  • Lipoatrophic diabetes mellitus

    Phase 3Status unknown2 trials

  • Type2 diabetes mellitus

    Phase 3Completed2 trials

All 12

Stopped

  • NCT02728453TerminatedType 2 diabetes

    Insufficient recruitment.

  • NCT02985242TerminatedType 2 diabetes

    difficulties to recruit planned numbers of patients within reasonable time frame

  • NCT05129722TerminatedHeart failure with preserved ejection fraction

    Difficulties in recruitment at both sites.

  • NCT06844669TerminatedBreast neoplasm

    Futility

  • NCT06818305TerminatedKidney neoplasm

    The patient enrollment rate is proceeding too slowly

  • NCT05282121TerminatedPortal hypertension

    Company decision

Who is developing empagliflozin?

3 companies: Boehringer Ingelheim, Nabiqasim Industries (Pvt) and Chong Kun Dang Pharmaceutical.

Companies
  • Boehringer IngelheimPhase 4type 2 diabetes, chronic kidney disease
  • Nabiqasim Industries (Pvt)Phase 4diabetes mellitus, type 2 DM
  • Chong Kun Dang PharmaceuticalPhase 4diabete type 2

Trial sponsors

Funding

19 grants since 2017

National Institute of Diabetes and Digestive and Kidney Diseases$2.9MNational Heart, Lung, and Blood Institute$3.5MSwiss National Science FoundationCHF 1.2M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Empagliflozin reduces cardiovascular and kidney events in human trials; frailty improves in one trial but shows no clear change in another. Independent labs find reduced senescence in cells, while mouse results include increases. Developers sponsor 92 trials across uses; 75 registered trials concern aging, while 71 across uses ended over a year ago without posted results or citing papers.

  2. Summary rewritten as its findings changed.

    As it read before

    Human trials report reduced frailty or no clear effect with empagliflozin; a trial reports reduced kidney disease progression or cardiovascular death. Independent labs report reduced senescence in cells, while mouse senescence results point both ways. Of registered trials, 76 concern aging; 71 across all uses ended over a year ago without posted results, and 93 of 297 have developer sponsorship.

  3. Summary rewritten as its findings changed.

    As it read before

    Independent cell studies report reduced cellular senescence with empagliflozin; a human trial reports less kidney disease progression or cardiovascular death, while human trials disagree on frailty. It has 42 aging-related trials; across all uses, 73 trials ended over a year ago without posted results or citing papers. Its developers sponsor 87 trials across uses.

  4. Summary rewritten as its findings changed.

    As it read before

    Independent labs report reduced cellular senescence with empagliflozin in cells; a human trial reports lower risk of kidney disease progression or cardiovascular death, while frailty results differ across human trials. Forty registered trials concern aging; 73 across uses ended over a year ago without posted results. Developer companies sponsor trials; Boehringer Ingelheim funds papers.

  5. Summary rewritten as its findings changed.

    As it read before

    Empagliflozin reduces senescence in cells across independent labs and in mice; a human trial reports less kidney disease progression or cardiovascular death, while frailty results differ. Of its registered trials, 36 concern aging; 73 across all uses ended over a year ago without posted results or citing papers. Boehringer Ingelheim funds some papers, and developers sponsor 87 of 288 trials.

Latest

Dec 2025: 14Jan 2026: 39Feb 2026: 30Mar 2026: 37Apr 2026: 5May 2026: 5Jun 2026: 8Jul 2026: 18Aug 2026: 22Sep 2026: 24Oct 2026: 71Nov 2026: 58331 papers in 12 months

See all 509 papers on empagliflozin